Van Cleef Asset Managementinc Stake in Gilead Sciences INC (GILD) Increased

April 17, 2018 - By Jenna Rose

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate LogoBig Money Sentiment decreased to 0.8 in Q4 2017. It has change of 0.23, from 2017Q3’s 1.03. The ratio fall due to GILD positioning: 95 sold and 545 reduced. 104 funds bought positions and 411 increased positions. Investors holded 957.62 million in 2017Q3 but now own 972.68 million shares or 1.57% more. Sg Americas Llc has invested 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD). Parsons Cap Management Ri holds 0.1% or 12,365 shs in its capital. Arrowgrass Capital Prtn (Us) LP has 190,766 shs for 0.13% of their capital. Denali Advsr Ltd Llc stated it has 141,303 shs. Rnc Capital Mgmt Ltd Llc accumulated 0.06% or 11,455 shs. Skba Cap Management Ltd has invested 1.98% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Aureus Asset Management Ltd Liability Company has 0.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Burt Wealth accumulated 2,669 shs. Peak6 Invs Lp, a Illinois-based fund reported 185,172 shs. California State Teachers Retirement Systems has 2.21 million shs for 0.33% of their capital. Eaton Vance Management holds 4.32 million shs or 0.75% of its capital. Hall Laurie J Trustee reported 0.06% stake. Nbt Comml Bank N A New York holds 0.23% in Gilead Sciences, Inc. (NASDAQ:GILD) or 20,409 shs. Moreover, Carnegie Asset Mngmt Limited Liability Com has 0.08% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,765 shs. Edgemoor Advsrs owns 132,383 shs.

GILD registered $39.51 million net activity with 0 buys and 17 selling transactions since January 2, 2018. The insider MARTIN JOHN C sold $3.66 million. $2.09 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shs were sold by Alton Gregg H. Cogan John Francis had sold 5,833 shs worth $434,384 on Friday, April 6. 5,000 shs were sold by Washington Robin L, worth $401,566. On Tuesday, January 16 the insider Meyers James R sold $8.02M.

The stake In Gilead Sciences Inc (GILD) was upped owned by Van Cleef Asset Managementinc. According to 2017Q4 Securities and Exchange form the reduction is 94.66%. The company’s stock popped up 1.93% while Van Cleef Asset Managementinc bought 63,096 shares. At the end of 2017Q4, the 129,752 shares of the health care company held by the institutional investor were priced at $9.30M, up from 66,656 at the end of the previous reported quarter. Van Cleef Asset Managementinc has cut its stake in and also reduced its holding in by shares in the quarter, for a total of shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

In total 15 analysts cover Gilead Sciences (NASDAQ:GILD). “Buy” rating has 8, “Sell” are 0, while 7 are “Hold”. 53% are bullish. With $103.0 highest and $77.0 lowest [Target] Gilead Sciences has $90.08 average [Target] or 20.61% above the current ($74.69) price. 27 are the (NASDAQ:GILD)’s analyst reports since October 19, 2017 according to StockzIntelligence Inc. On Thursday, November 30 the rating was upgraded by Maxim Group to “Buy”. On Wednesday, February 7 the firm has “Market Perform” rating given by Leerink Swann. On Tuesday, January 16 the rating was upgraded by Wells Fargo to “Outperform”. On Wednesday, January 3 Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Hold” rating. On Monday, November 13 the firm has “Hold” rating given by Argus Research. The company rating was upgraded by Citigroup on Tuesday, January 30. On Friday, October 27 BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Outperform” rating. The company rating was maintained by Jefferies on Friday, October 27. On Wednesday, October 18 the rating was maintained by Cowen & Co with “Buy”. The company rating was maintained by Cowen & Co on Wednesday, February 7.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: